AAA June 2017 – Page 3

Johnson & Johnson funds Provention in private placement

US-based biopharmaceutical company Provention Bio has raised $28.4m through a private placement featuring Johnson & Johnson Innovation – JJDC, a subsidiary of pharmaceutical group Johnson & Johnson. MDB Capital Group, the company builder that co-founded Provention, was placement agent for the offering, which included diabetes research finance organisation JDRF’s T1D Fund. Provention is developing therapeutics… Continue reading Johnson & Johnson funds Provention in private placement